Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering.

abstract：:The incidence of thyroid cancer is increasing by 4% per year. Thyroid cancer has become the eighth most common malignancy diagnosed in women. Papillary cancer accounts for 80% of all thyroid cancer. The management of papillary thyroid cancer is challenging, primarily because there have been no prospective randomized t...

journal_title：Expert review of anticancer therapy

authors： Rosenbaum MA,McHenry CR

更新日期：2009-03-01 00:00:00

abstract：:Interview by Sophia Maprayil and Alexandra Hemsley, Commissioning Editors Chris Twelves is a medical oncologist and leads the Section of Oncology and Clinical Research at Cancer Research UK's Clinical Centre at St James's Hospital, Leeds. His particular interest lies in new drug development and clinical pharmacology; ...

journal_title：Expert review of anticancer therapy

authors： Twelves C

更新日期：2013-03-01 00:00:00

abstract：:B cells play an important role in the pathogenesis of certain lymphomas and leukemias, as well as many autoimmune diseases. Antagonistic B-cell antibodies are thus gaining an increasing role in the management of these diseases. The first antibody target in this regard was CD20, with the development and introduction of...

journal_title：Expert review of anticancer therapy

authors： Goldenberg DM

更新日期：2006-10-01 00:00:00

abstract：:Tamoxifen has been shown to reduce the incidence of estrogen receptor-positive breast cancer by approximately 50% in high-risk women. Similar results are seen for raloxifene, but it has a more favorable side-effect profile. Data on contralateral tumors from women in adjuvant trials treated with aromatase inhibitors su...

journal_title：Expert review of anticancer therapy

authors： Cuzick J

更新日期：2008-09-01 00:00:00

abstract：:Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase I...

journal_title：Expert review of anticancer therapy

authors： Surmont VF,van Meerbeeck JP

更新日期：2011-10-01 00:00:00

abstract：:The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

journal_title：Expert review of anticancer therapy

authors： Greenberg CC,Bafford AC,Golshan M

更新日期：2008-02-01 00:00:00

abstract：:The treatment of metastatic colorectal cancer is evolving. Although the advent of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients, surgical resection in certain subsets of patients with advanced colorectal cancer is the only chance for long-term survival. Traditionally, pa...

journal_title：Expert review of anticancer therapy

authors： Shen P,Stewart JH,Levine EA

更新日期：2008-11-01 00:00:00

abstract：INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...

journal_title：Expert review of anticancer therapy

authors： Amaral T,Nouri N,Garbe C

更新日期：2016-07-01 00:00:00

abstract：:A number of cancers occur with increased frequency in individuals with HIV infection. There is a debate as to whether or not hepatocellular cancer is one of these tumors. This article reviews the current data regarding incidence etiology, treatment and outcome for HIV-related hepatocellular cancer. It also attempts to...

journal_title：Expert review of anticancer therapy

authors： Powles T,Macdonald D,Nelson M,Stebbing J

更新日期：2006-11-01 00:00:00

abstract：:Nonmelanoma skin cancer is the most prevalent malignant disease among light-skinned individuals in the USA, accounting for approximately 1 million new cases annually. Solar ultraviolet radiation is known to be the major cause of skin cancer. The idea that diet, particularly dietary fat, may play a role in modulating c...

journal_title：Expert review of anticancer therapy

authors： Black HS

更新日期：2005-10-01 00:00:00

abstract：:Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...

journal_title：Expert review of anticancer therapy

authors： Quinn DI,Vaishampayan U,Higano CS,Lin DW,Shore ND,Beer TM

更新日期：2014-01-01 00:00:00

abstract：:Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air o...

journal_title：Expert review of anticancer therapy

authors： Taivans I,Bukovskis M,Strazda G,Jurka N

更新日期：2013-12-13 00:00:00

abstract：INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm. The incidence of ICC has been increasing world-wide over the past several decades. Areas covered: The pathogenesis of ICC is a complex process involving the alteration of specific genes and epigenetic changes. This review summarizes the ...

journal_title：Expert review of anticancer therapy

authors： Huang SB,Zheng CX

更新日期：2017-01-01 00:00:00

abstract：:Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

journal_title：Expert review of anticancer therapy

authors： Micali G,Lacarrubba F,Bhatt K,Nasca MR

更新日期：2013-12-01 00:00:00

abstract：INTRODUCTION:Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and ...

journal_title：Expert review of anticancer therapy

authors： Feld J,Belasen A,Navada SC

更新日期：2020-06-01 00:00:00

abstract：:The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemotherapy have been push...

journal_title：Expert review of anticancer therapy

authors： Kell J

更新日期：2016-01-01 00:00:00

abstract：:The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...

journal_title：Expert review of anticancer therapy

authors： Camara-Clayette V,Hermine O,Ribrag V

更新日期：2012-09-01 00:00:00

abstract：:Proteasome inhibition has been shown to be an effective strategy for the treatment of multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent bortezomib. Recently, the second-generation proteasome inhibitor carfilzomib has been approved in the USA in the relapsed and refractory setting, ...

journal_title：Expert review of anticancer therapy

authors： McBride A,Ryan PY

更新日期：2013-03-01 00:00:00

abstract：:Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorab...

journal_title：Expert review of anticancer therapy

authors： Rocco D,Della Gravara L,Battiloro C,Gridelli C

更新日期：2019-07-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer-related deaths in the Western world. The lungs can be affected by a number of histologically diverse malignancies. Nonetheless, the vast majority of lung cancers are classified as non-small-cell lung cancer (NSCLC). Despite extensive research on different therapeutic regimens...

journal_title：Expert review of anticancer therapy

authors： Galluzzo P,Bocchetta M

更新日期：2011-04-01 00:00:00

abstract：:Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer. Optimizing the management of frequent crizotinib-related adverse events is crucial to ensure its continuous administration and reprodu...

journal_title：Expert review of anticancer therapy

authors： Girard N,Audigier-Valette C,Cortot AB,Mennecier B,Debieuvre D,Planchard D,Zalcman G,Moro-Sibilot D,Cadranel J,Barlési F

更新日期：2015-02-01 00:00:00

abstract：INTRODUCTION:The treatment landscape of metastatic prostate cancer has changed dramatically over the past five years. As new discoveries are made and further novel therapies become available, there is a heightened urgency to develop biomarkers that can guide prognoses and predict therapy responses. Circulating tumor ce...

journal_title：Expert review of anticancer therapy

authors： Parimi S,Ko JJ

更新日期：2017-10-01 00:00:00

abstract：:Accelerated partial breast irradiation has been investigated in selected patients with early-stage breast cancer. Accelerated partial breast irradiation limits the radiation target to the volume of tissue immediately surrounding the lumpectomy cavity and reduces the overall treatment time from approximately 6 weeks to...

journal_title：Expert review of anticancer therapy

authors： Cuttino LW,Vicini FA

更新日期：2011-09-01 00:00:00

abstract：:Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel-based chemotherapy. Two agents (cabazitaxel and abiraterone) are already accessible to prescribers, having shown survival be...

journal_title：Expert review of anticancer therapy

authors： Birtle A

更新日期：2013-01-01 00:00:00

abstract：:A major issue with current cancer therapy is how to ensure the maximum benefit with minimum toxicity for individual patients. With the progress of the human genome project have come high-throughput technologies for the analysis of DNA, gene expression or tumor protein in an efficient and quantitative manner. This revi...

journal_title：Expert review of anticancer therapy

authors： McLeod HL

更新日期：2002-02-01 00:00:00

abstract：:Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

journal_title：Expert review of anticancer therapy

authors： Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

更新日期：2006-06-01 00:00:00

abstract：:Squamous cell carcinoma of the vulva is a rare disease, accounting for approximately 5% of cancers of the female genital tract. Standard therapy for early-stage vulvar cancer mainly comprises of surgery of the vulva and groins. In locally advanced or metastatic vulvar cancer, neoadjuvant or definitive chemoradiation i...

journal_title：Expert review of anticancer therapy

authors： Mahner S,Prieske K,Grimm D,Trillsch F,Prieske S,von Amsberg G,Petersen C,Mueller V,Jaenicke F,Woelber L

更新日期：2015-06-01 00:00:00

abstract：INTRODUCTION:Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly en...

journal_title：Expert review of anticancer therapy

authors： Buchanan T,Mutch D

更新日期：2019-01-01 00:00:00

abstract：:For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

journal_title：Expert review of anticancer therapy

authors： Murawski N,Zwick C,Pfreundschuh M

更新日期：2010-03-01 00:00:00

abstract：:Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality, despite advances in surgical and chemotherapeutic management. The molecular pathways that control angiogenesis have been demonstrated to be key to the pathogenesis of EOC, and have been shown to have prognostic significance. Incr...

journal_title：Expert review of anticancer therapy

authors： Collinson FJ,Hall GD,Perren TJ,Jayson GC

更新日期：2008-01-01 00:00:00